Because the state where I live has only recently approved the use of medical marijuana, I haven’t had the opportunity to try it for my MS. From what I’ve read, various blends of medical marijuana have helped a lot of people deal with their MS symptoms. But not many significant clinical trials have been conducted, as far as I know, on the effects of marijuana on our disease. Here’s one of medical marijuana in chewing gum form that’s gearing up in the Netherlands.
Dutch regulators have signed off on AXIM Biotechnologies’ clinical trial plans for a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity.
The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials.
One single session of non-invasive brain stimulation can reduce cognitive fatigue in patients with multiple sclerosis (MS), say researchers at Germany’s Otto-von-Guericke University Magdeburg.
According to a Turkish study, certain MS patients are more likely than others to return to their pretreatment disease activity level if they stop using Gilenya as their disease-modifying therapy (DMT). But I regularly read about people who have gone off other DMTs and, as a result, have regressed. So, it seems to me that a broader study, involving various DMTs, is needed to put this into some perspective.
Multiple sclerosis patients with high relapse rates but less physical impairment before starting on Novartis’ Gilenya (fingolimod) are likely to experience a surge in disease activity if they stop the treatment, researchers in Turkey report.
The study, which dealt with patients with relapsing forms of MS, referred to the surge as “severe disease reactivation,” or SDR.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?